Effect of sorbitol dehydrogenase inhibition on experimental diabetic autonomic neuropathy

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 12, 1998, Pages 1175-1189

  Schmidt, Robert E ^a,b   Dorsey, Denise A ^a   Beaudet, Lucie N ^a   Plurad, Santiago B ^a   Williamson, Joseph R ^b   Ido, Yasuo ^b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic neuropathy; Neuroaxonal dystrophy; Sorbitol dehydrogenase; Sympathetic

Indexed keywords

CP 166572; ENZYME INHIBITOR; IDITOL DEHYDROGENASE; UNCLASSIFIED DRUG; ZOPOLRESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTONOMIC NEUROPATHY; CONTROLLED STUDY; DIABETIC NEUROPATHY; ENZYME INHIBITION; HISTOPATHOLOGY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT;

EID: 0031774461     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199812000-00010     Document Type: Article

References (70)

1. Dyck PJ, Giannini C. Pathologic alterations in the diabetic neuropathies. J Neuropathol Exp Neurol 1996;55:1181-93
2. Rundles RW. Diabetic neuropathy: General review with report of 125 cases. Medicine (Baltimore) 1945;24:111-60
3. Hosking DJ, Bennett T, Hampton JR. Diabetic autonomic neuropathy. Diabetes 1978;27:1043-55
4. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Quart J Med 1980;49:95-108
5. Vinik AI, Holland MT, LeBeau JM, Liuzzi FJ, Stansberry KB, Colen LB. Diabetic Neuropathies. Diabetes Care 1992;15:1926-75
6. Greene DA, Sima AAF, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992;15:1902-25
7. Low PA, Tuck RR, Takeuchi M. Nerve microenvironment in diabetic neuropathy, In: Diabetic neuropathy, Dyck PJ, Thomas PK, Asbury AK, Winegrad AI, Porte D, eds. Philadelphia: WB Saunders, 1987:266-78
8. Chang K, Ido Y, LeJeune W, Williamson JR, Tilton RG. Increased sciatic nerve blood flow in diabetic rats: Assessment by "molecular" versus particulate microspheres. Am J Physiol 1997;273: E164-73
9. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end-products in tissue and the biochemical basis of diabetic complications. New Engl J Med 1988;318:1315-21
10. Schmidt RE, Matschinsky FM, Godfrey DA, Williams AD, McDougal DB Jr. Fast and slow axoplasmic flow in sciatic nerves of diabetic rats. Diabetes 1975;24:1081-85
11. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In: Peripheral neuropathy, Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF, eds. Philadelphia: WB Saunders, 1993:1219-50
12. Fernyhough P, Diemel LT, Hardy J, Brewster WJ, Mohiuddin L, Tomlinson DR. Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur J Neurosci 1995;7:1107-10
13. 125I-Nerve Growth Factor in rats with streptozotocin-induced diabetes. Diabetes 1983;32: 654-63
14. Jakobsen J, Brimijoin S, Skau K, Sidenius P, Wells D. Retrograde axonal transport of transmitter enzymes, fucose-labeled protein and nerve growth factor in streptozotocin-diabetic rats. Diabetes 1981; 30:797-803
15. Hellweg R, Hartung H-D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: A possible role for NGF in the pathogenesis of diabetic neuropathy. J Neurosci Res 1990;26:258-67
16. Rabinowe SL, Brown FM, Watts M, Smith AM. Complement-fixing antibodies to sympathetic and parasympathetic tissues in IDDM. Diabetes Care 1990;13:1084-88
17. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801-13
18. Greene DA, Lattimer S, Ulbrecht J, Carroll P. Glucose-induced alterations in nerve metabolism: Current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 1985;8:290-99
19. Tomlinson DR, Townsend J, Fretten P. Prevention of defective axonal transport in streptozocin-diabetic rats by treatment with "Statil" (ICI 128436), an aldose reductase inhibitor. Diabetes 1985;34: 970-72
20. Tomlinson DR, Moriarty RJ, Mayer JH. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor sorbinil. Diabetes 1984;33:470-76
21. Gillon KRW, Hawthorne JN. Sorbitol, inositol and nerve conduction in diabetes. Life Sci 1983;32:1943-47
22. Yue DK, Hanwell MA, Satchell PM, Turtle JR. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats. Diabetes 1982;31:789-94
23. Schmidt RE, Plurad SB, Sherman WR, Williamson JR, Tilton RG. Effects of aldose reductase inhibitor sorbinil on neuroaxonal dystrophy and levels of myo-inositol and sorbitol in sympathetic autonomic ganglia of streptozocin-induced diabetic rats. Diabetes 1989;38:569-79
24. Schmidt RE, Plurad SB, Coleman BD, Williamson JR, Tilton RG. Effects of sorbinil, dietary myo-inositol supplementation and insulin on resolution of neuroaxonal dystrophy in mesenteric nerves of streptozocin-induced diabetic rats. Diabetes 1991;40:574-82
25. Greene DA, Lattimer SA. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation. J Clin Invest 1983;72:1058-63
26. Lee S-M, Schade SZ, Doughty CC. Aldose reductase, NADPH and NADP+ in normal, galactose-fed and diabetic rat lens. Biochim Biophys Acta 1985;841:247-53
27. Kinoshita JH, Nishimura C. The involvement of aldose reductase in diabetic complications. Diabetes Metab Rev 1988;4:323-37
28. Schmidt RE, Scharp DW. Axonal dystrophy in experimental diabetic autonomie neuropathy. Diabetes 1982;31:761-70
29. Schmidt RE, Plurad SB. Ultrastructural and biochemical characterization of autonomic neuropathy in rats with chronic streptozotocin diabetes. J Neuropathol Exp Neurol 1986;45:525-44
30. Schmidt RE, Chae HY, Parvin CA, Roth KA. Neuroaxonal dystrophy in aging human sympathetic ganglia. Am J Pathol 1990;136: 1327-38
31. Eades DM, Williamson JR, Sherman WR. Rapid analysis of sorbitol, galactitol, mannitol and myo-inositol mixtures from biological sources. J Chromatogr 1989;490:1-8
32. Ameyama M. Enzymic microdetermination of D-glucose, D-fructose, D-gluconate, 2-keto-D-gluconate, aldehyde, and alcohol with membrane bound dehydrogenases. In: Wood WA, ed. Methods in enzymology: Carbohydrate Metabolism. New York: Academic Press, 1982;89:20-9
33. Soyama K, Etsuko O. Improved procedure for determining serum D-arabinitol by resazurin-coupled method. Clin Chim Acta 1987; 168:259-60
34. SAS User's Guide: The NPARIWAY procedure. In: Statistics. Version 5 Edition. Chapter 26. Cary, NC, SAS Inst., 1985, 607-14
35. Schmidt RE, Plurad SB, Modert CW. Experimental diabetic autonomic neuropathy. Characterization in streptozotocin-diabetic Sprague-Dawley rats. Lab Invest 1983;49:538-52
36. Geisen K, Utz R, Grotsch H, Lang HJ, Nimmesgern H. Sorbitol-accumulating pyrimidine derivatives. Arzneim-Forsch 1994;44: 1032-43
37. Oates P, Williamson J, Chang K, et al. Attenuation of diabetes-induced vascular dysfunction by an inhibitor of sorbitol dehydrogenase. Diabetes 1994;43 (Suppl 1):17A
38. Tilton RG, Chang K, Nyengaard JR. Van den Enden M, Ido Y, Williamson JR. Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats. Diabetes 1995;44:234-42
39. Yagihashi S, Sima AAF. Diabetic autonomic neuropathy - the distribution of structural changes in sympathetic nerves of the BB rat. Am J Pathol 1985;121:138-47
40. Sima AAF, Yagihashi S. Central-peripheral distal axonopathy in the spontaneously diabetic BB-rat: Ultrastructural and morphometric findings. Diab Res Clin Pract 1986;1:289-98
41. Schmidt, RE. Neuroaxonal dystrophy in aging rodent and human sympathetic autonomie ganglia: Synaptic pathology as a common theme in neuropathology. Adv Pathol Lab Med 1993;6:505-22
42. Clark HB, Schmidt RE. Identification of dystrophic sympathetic axons in experimental diabetic autonomie neuropathy. Brain Research 1984;293:390-95
43. Scott LD, Ellis TM. Small intestinal transit and myoelectric activity in diabetic rats. In: Gastrointestinal motility, Christensen J, ed. New York: Raven Press, 1980:395-99
44. Chang EM, Fedorak RN, Field M. Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. Gastroenterol 1986;91:364-69
45. Petersen A, Szwergold BS, Kappler F, Weingarten M, Brown TR. Identification of sorbitol-3-phosphate and fructose-3-phosphate in normal and diabetic human erythrocytes. J Biol Chem 1990;265: 17424-27
46. Oates PJ, Ido Y, Mylari BL, Williamson JR. Peripheral neuropathy in diabetic rats is prevented by inhibition of sorbitol dehydrogenase or aldose reductase. (Abstract) Diabetologia 1995;38 (Suppl 1):A232
47. Powell HC, Garrett RS, Kador PF, Mizisin AP. Fine-structural localization of aldose reductase and oubain-sensitive, K(+)-dependent p-nitro-phenylphosphatase in rat peripheral nerve. Acta Neuropathol 1991;81:529-39
48. Chandler CE, Miller LJ. Studies of aldose reductase using neuronal cell culture and ligated rat sciatic nerve. Metabolism 1986;35 (Suppl. 1):71-77
49. Ido Y, Ostrow E, Mylari BL, Oates PJ, Williamson JR. Decreased motor nerve conduction velocity (MNCV) in diabetic rats is linked to cytosolic reductive stress. (Abstract) Diabetologia 1997;40 (Suppl 1):A33
50. Obrosova I, Marvel J, Faller AM, Williamson JR. Reductive stress is a very early metabolic imbalance in sciatic nerve in diabetic and galactose-fed rats. (Abstract) Diabetologia 1995;38 (Suppl 1):A8
51. Ido Y, Oates PJ, Mylari BL, et al. Inhibitors of sorbitol dehydrogenase and aldose reductase prevent impaired nerve conduction in diabetic rats. (Abstract) Diabetologia 1996;39 (Suppl 1):A248
52. Obrosova I, Faller A, Burgan J, Ostrow E, Williamson JR. Glycolytic pathway, redox state of NAD-couples, and energy metabolism in lens in galactose-fed rats: Effect of an aldose reductase inhibitor. Curr Eye Res 1996;16:34-43
53. Berry GT, Wehrli S, Reynolds R, et al. Elevation of erythrocyte redox potential linked to galactonate biosynthesis: Elimination by tolrestat. Metabolism, in press
54. Nyengaard JR, Gates PJ, Mylari BL, Williamson JR. Inhibition of sorbitol dehydrogenase prevents reductive stress caused by glucose and sorbitol but not by galactose. Diabetologia 1995;38 (Suppl 1):A276
55. Myers RR, Powell HC. Galactose neuropathy: Impact of chronic endoneurial edema on nerve blood flow. Ann Neurol 1984;16:587-94
56. Ido Y, Chang K, LeJeune W, Tilton RG, Williamson, JR. Diabetes impairs sciatic nerve hyperemia induced by surgical trauma: (Patho)physiological implications for diabetic neuropathy. Am J Physiology 1997;273:E174-84
57. Williamson JR, Chang K, Oates P et al. Diabetes-induced vascular dysfunction is prevented by inhibition of sorbitol dehydrogenase. Diabetologia 1994;37 (Suppl 1):A23
58. Cameron NE, Cotter MA, Basso M, Hohman TC. Comparison of the effect of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol metabolites in streptozocin-diabetic rats. Diabetologia 1997; 40:271-81
59. Cameron NE, Cotter MA, Dines KC, Maxfield EK, Carey F, Mirrlees DJ. Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: Dose-response considerations and independence from a myo-inositol mechanism. Diabetologia 1994;37:651-63
60. Sima AAF, Dunlap JA, Davidson EP, et al. Supplemental myoinositol prevents L-fucose-induced diabetic neuropathy. Diabetes 1997;46:301-6
61. Greene DA, Mackway AM. Decreased myo-inositol content and Na+K+-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition. Diabetes 1986;35:1106-8
62. Llewelyn JG, Simpson CMF, Thomas PK, King RHM, Hawthorne JN. Changes in sorbitol, myo-inositol and lipid inositol in dorsal root and sympathetic ganglia from streptozotocin-diabetic rats. Diabetologia 1986;29:876-81
63. Lambourne JE, Tomlinson DR, Brown AM, Willars GB. Opposite effects of diabetes and galactosaemia on adenosine triphosphatase activity in rat nervous tissue. Diabetologia 1987;30:360-62
64. Greene DA, Lattimer SA. Altered myo-inositol metabolism in diabetic nerve. In Diabetic Neuropathy. Dyck PJ, Thomas PK. Asbury AK, Winegrad AI, Porte D, Jr., eds. Philadelphia: W.B. Saunders, 1987:266-78
65. Stevens MJ, Lattimer SA, Kamijo M, Van Huysen C, Sima AAF, Greene DA. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993;36:608-14
66. Tomlinson DR, Townsend J, Fretten P. Prevention of defective axonal transport in streptozocin-diabetic rats by treatment with "Statil" (ICI 128436), an aldose reductase inhibitor. Diabetes 1985;34: 970-72
67. Way KJ, Reid JJ. The aldose reductase inhibitor does not prevent the impairment in nitric oxide-mediated neurotransmission in anococcygeus muscle from diabetic rats. Eur J Pharmacol 1996;318: 101-8
68. Yoshida T, Nishioka H, Yoshioka K, Nakano K, Kondo M, Terashima H. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Diabetes 1987;36:6-13
69. Tilton RG, Chang K, Pugliese G, et al. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989;38:1258-70
70. Cameron NE, Cotter MA. Dissociation between biochemical and functional effects of the aldose reductase inhibitor, ponalrestat, on peripheral nerve in diabetic rats. Br J Pharmacol 1992;107:939-44